

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Please cancel Claims 1-16.

17. (New) A method of preventing radiation-induced cystitis of the bladder area comprising instilling into the bladder of a human or an animal, a composition comprising hyaluronic acid having an average molecular weight of not less than about 2×10^5 Daltons, a pharmaceutically acceptable carrier, and an agent, wherein the agent is an antiseptic, antibacterial, antifungal, immunotherapeutic, immunosuppressive, chemotherapeutic, or pH modifying agent, wherein the instillation of the composition is followed by administering radiotherapy treatment to the bladder area.

18. (New) The method of claim 17, wherein the agent is an antibacterial.

19. (New) The method of claim 17 wherein the antibacterial is aminoglycoside, cephalosporin, gentamycin, macrolide, nitrofurantoin, penicillin, quinolone, suphonamide, tetracycline, trimethoprim, bacitracin, neomycin, chlorhexidine, or mandelamine.

20. (New) The method of claim 17, wherein the agent is an antifungal.

21. (New) The method of claim 17, wherein the antifungal is amphotericin B or fluconazole.

22. (New) The method of claim 17, wherein the agent is an immunotherapeutic.

Preliminary Amendment

23. (New) The method of claim 17, wherein the immunotherapeutic is bacterial cell extracts, mycobacterial cell wall extracts, live and inactivated bacillus Calmette-Guerin, bacillus Calmette-Guerin extracts, cytokines, interferons, interleukins, prostaglandins, or immune stimulants of viral, chemical and molecular biological origin effective for treating disorders of the bladder.

24. (New) The method of claim 17, wherein the agent is an immunosuppressive.

25. (New) The method of claim 17, wherein the immunosuppressive is a prostaglandin or corticosteroid.

26. (New) The method of claim 17, wherein the agent is a chemotherapeutic.

27. (New) The method of claim 17, wherein the chemotherapeutic is cisplatin, cyclophosphamide, doxorubicin, vincristin, mitomycin-C or thiotepa.

28. (New) The method of claim 17, wherein the agent is a pH modifying agent.

29. (New) The method of claim 17, wherein the pH modifying agent is sodium acid phosphate or sodium bicarbonate.

30. (New) The method of claim 17, wherein the agent is a glycosaminoglycan.

31. (New) The method of claim 17, wherein the glycosaminoglycan is heparin, heparan sulfate, pentosanpolysulfate, dermatan sulfate, chondroitin sulfate and keratanosulfate.